The DOI matches its Crossref record.
Restenosis: Delineating the Numerous Causes of Drug-Eluting Stent Restenosis
Open accessAbstract
I n the past decade, tremendous progress has been made in reducing the incidence of restenosis with the advent of the drug-eluting stent (DES).With "plain old balloon angioplasty," rates of acute and chronic vessel occlusion were unacceptably high at Ϸ30% to 60%, secondary to acute and chronic recoil and constrictive remodeling.The advent of bare-metal stents (BMS) appeared to eliminate the issue of acute and chronic recoil but introduced a new entity, neointimal hyperplasia (NIH), with classical papers unequivocally demonstrating a strong and linear relationship between NIH formation and late lumen loss (LLL).The restenosis rates with BMS were reported to be between 16% and 44%, with higher rates of stenosis attributable to several risk factors, in particular, long lesion length and small vessel caliber. 1 DES were thus conceived as the next step in tackling this iatrogenic entity of NIH, with large-scale reductions in restenosis rates reported at 0% in highly selective lesions and up to 16% in a broader range of patients and lesions with first-generation DES. 1 In contrast to plain old balloon angioplasty and BMS, in which an almost classical gaussian distribution of LLL is seen postprocedurally, the LLL after DES implantation appears to follow a bimodal pattern of distribution (Figure 1). 2 Despite the significant advances in the technology to reduce DES restenosis, conservative estimates still suggest that the incidence of in-stent restenosis (ISR) requiring target vessel revascularization (TVR), so-called DES failure, to be Ϸ5% to 10%, with one estimate suggesting Ϸ200 000 repeat revascularizations in the United States alone.3 Whereas the pattern of restenosis in BMS has been shown to be primarily diffuse, with DES it has been demonstrated to be usually focal (Figure 2) and most commonly located at the proximal DES edge, as demonstrated in Ͼ60% of ISR with either paclitaxel-eluting stent (PES) or sirolimus-eluting stent (SES) implantation.However, over one-fifth of ISR cases remain diffuse, and 10% to 20% are even occlusive.4 In 2004, the first report of risk factors associated with DES restenosis in patients with the unrestricted use of SES since approval of its CE mark was made by our group.Despite the apparent differences in the distribution of LLL between BMS and DES as previously described, the main message of these and subsequent findings was that the usual patient character-istics, lesion types, and procedural factors incriminated with restenosis in BMS were equally responsible with DES, with diabetes mellitus implicated as one of the strongest risk factors.It should however be emphasized that the "slope" of the distribution of restenosis with DES appears to be much flatter compared with BMS, especially in long lesions and small vessels, highlighting the importance of drug elution in potentially attenuating the NIH response.3 Histopathologic analyses of in-stent neointima taken by directional atherectomy at the time of reintervention also have been shown to be remarkably similar between BMS and DES.This is almost exclusively composed of proteoglycanrich smooth muscle cells (SMCs) and fibrolipidic areas rich in collagen and reticular fibers.A more "immature" restenotic process, as evidenced by differences in SMC phenotypes, however, has been shown to potentially exist with certain types of DES compared with BMS.5,6 ISR traditionally has been suggested as being potentially less benign with the recurrence of anginal symptoms alone.However, emerging evidence now suggests that between 30% and 60% of ISR cases present with an acute coronary syndrome with unstable angina being the most common presentation and up to 5% of patients even reported to present with ST-elevation myocardial infarction (STEMI).7,8 However, one series has suggested no differences in the incidence of acute coronary syndrome associated with either BMS or DES restenosis.7 The treatment of ISR and the determinant factors involved in the development of late stent thrombosis (LST) are well described elsewhere and are outside the scope of this review.3,9 The underlying mechanisms of restenosis with DES can broadly be divided into 4 main causes (Table), namely, biological, arterial, stent, and implantation factors, accepting that this classification is somewhat arbitrary and that mechanisms of restenosis may be attributable to more than one factor.In this review we explore these 4 main mechanisms and identify the potentially controllable and noncontrollable factors from the perspective of the interventional cardiologist intending to implant a DES. Biological Factors Resistance to Antiproliferative DrugsThe underlying mechanisms of action and causes of resistance to paclitaxel or sirolimus are well documented in the
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Giustino, G., Colombo, A., Camaj, A., Yasumura, K., Mehran, R., Stone, G. W., Kini, A., & Sharma, S. K. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.05.017 · Cited by 413
Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity
Frismantiene, A., Philippova, M., Erne, P., & Resink, T. J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.08.019 · Cited by 406
Serruys, P. W., Farooq, V., Kalesan, B., de Vries, T., Buszman, P., Linke, A., Ischinger, T., Klauss, V., Eberli, F., Wijns, W., et al. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.04.011 · Cited by 331
Self-citationKushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48
Towards 3D in vitro models for the study of cardiovascular tissues and disease
Ryan, A. J., Brougham, C. M., Garciarena, C. D., Kerrigan, S. W., & O’Brien, F. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.014 · Cited by 42
Metadata
- Authors
- Farooq, V., Gogas, B. D., & Serruys, P. W.
- Venue
- Circulation: Cardiovascular Interventions
- Published
- 2011-04
- Volume
- 4
- Issue
- 2
- Pages
- 195-205
- ISSN
- 1941-7632 (ISSN-L)
- 1941-7640
- OpenAlex
- W1964964525
- Cited by
- 191
- References
- 0
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Restenosis: Delineating the Numerous Causes of Drug-Eluting Stent Restenosis. https://app.cochat.ai/papers/10.1161/circinterventions.110.959882
- The paper
- Farooq, V., Gogas, B. D., & Serruys, P. W. (2011). Restenosis: Delineating the Numerous Causes of Drug-Eluting Stent Restenosis. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.110.959882
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.